Commercial transformation across European life sciences
Pharma, MedTech, Digital Health and AI.

Life Sciences Commercial Transformation in Europe: Strategy, Market Signals, and What Comes Next

Commercialization, regulation, AI, and operating-model shifts shaping pharma, MedTech, and digital health in Europe – from an operator’s perspective.

Read the Weekly Signal About Piotr Wrzosinski

Weekly Life Sciences Signal

Weekly analysis of funding, regulation, AI, commercial moves, and execution signals shaping life sciences in Europe.

• Weekly Signal

  Europe Life Sciences Weekly Signal #42: Care Moves Out of the Hospital

  ByPiotr Wrzosinski 21/06/202621/06/2026

  Week of 15–21 June 2026 Quiet week? Only if you confuse noise with signal. There was no CHMP plenary and no completed mega-deal. But the week’s most useful signals pointed in the same direction: life sciences value is moving from the asset to the delivery model. GSK secured US approval for the first oral carbapenem…

• Weekly Signal

  Europe Life Sciences Weekly Brief #41: The Premium on Certainty

  ByPiotr Wrzosinski 14/06/202614/06/2026

  Week of 8–14 June 2026 This was a week about the price of proof. GSK paid a premium for late-stage oncology assets already under FDA review. Roche put serious money behind a validated target through a newer modality. Europe’s medicines regulators made reliability the centre of the AI conversation. The UK edged closer to a…

• Weekly Signal

  Europe Life Sciences Weekly Signal #40: The Bottleneck Moves Downstream

  ByPiotr Wrzosinski 07/06/202607/06/2026

  Week of 1–7 June 2026 This was a week of things being declared ready. Merck arrived at ASCO with a clearer post-Keytruda oncology portfolio story. Brussels set up the expert bodies that will support AI Act enforcement. Semble raised £30m to scale a platform already embedded in UK care delivery. Sanofi brought Biogen into a…